Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-197283
Filing Date
2026-04-30
Accepted
2026-04-30 16:10:38
Documents
18
Period of Report
2026-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A ntla-20260430.htm   iXBRL DEF 14A 2490983
2 GRAPHIC img80879272_0.gif GRAPHIC 13600
3 GRAPHIC img80879272_1.gif GRAPHIC 13600
4 GRAPHIC img80879272_2.jpg GRAPHIC 46022
5 GRAPHIC img80879272_3.jpg GRAPHIC 61211
6 GRAPHIC img80879272_4.jpg GRAPHIC 175365
7 GRAPHIC img80879272_5.jpg GRAPHIC 195109
  Complete submission text file 0001193125-26-197283.txt   4512693

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20260430.xsd EX-101.SCH 26684
21 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20260430_htm.xml XML 196321
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37766 | Film No.: 26925383
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)